prostate cancer detection Articles
-
Design and analysis of nanowire sensor array for prostate cancer detection
Prostate cancer is one of the major cancer affecting men in India. After lung cancer, prostate cancer has caused large number of deaths in India. Nanowire is the biosensor used for detection of cancer. In this paper, we present a design of nanowire array sensor for prostate cancer detection. A sensor array of 8 × 8 elements is designed to capture the PSA present in the blood that helps in ...
-
An independent assessment of AI for prostate cancer detection - Case Study
Yale Medicine, an academic medical center with a high volume of prostate biopsies, conducted a study to determine Paige Prostate’s utility as a prescreening tool for clinical use. A total of 1,876 prostate core biopsy slides were analyzed by Paige Prostate, and only those cores categorized by the AI as “suspicious” or as out of distribution were manually reviewed by Yale ...
-
Evaluation of an Epigenetic Assay for Predicting Repeat Prostate Biopsy Outcome in African American Men
Abstract Objective: To evaluate an epigenetic assay performed on tissue from negative prostate biopsies in a group of African American (AA) men undergoing repeat biopsy, and to compare accuracy for predicting repeat biopsy outcome to prior studies conducted in predominantly Caucasian populations. Materials and methods: The study population consisted of 211 AA men from 7 urology centers ...
By MDxHealth
-
Blinded Validation Projectfor Prostate Cancer Test Johns Hopkins University Medical Center, Brady Urology Institute
Summary OTraces, in collaboration with the Johns Hopkins Medical Center, Brady Urology Institute (JHMC), performed a blinded validation study on OTraces prostate cancer (PCa) detection products. The blinded validation project involves two phases, and the first has been completed: Phase I: Blinded third party validation of the test for men with aggressive PCa, Gleason score of 7(4+3), 8, 9, and ...
By OTraces Inc.
-
How Has the COVID-19 Pandemic Affected Prostate Cancer Care?
#CancelEverything On March 11, 2020, the World Health Organization (WHO) declared the coronavirus 2019 disease (COVID-19) a global pandemic. Its impact left the world uncertain about health, politics and the economy. The first wave caused a major disruption to health services, exacerbating concerns of patient and physician safety and resource availability. On trend with the “cancel ...
-
Low-dose irradiation for controlling prostate cancer
Prostate cancer is the second most commonly diagnosed cancer among North American men and the second leading cause of death in those aged 65 and over. The US Cancer Society recommends testing those over 50 years of age who are expected to live at least for 10 years, even though the ability of early detection to decrease prostate cancer mortality has not been demonstrated. A controversy exists ...
-
Nanostics Announces Study Data Supporting ClarityDX Prostate as a Reflex Test to Predict Clinically Significant Prostate Cancer
Real-world data shows that at a 94% sensitivity level for prostate cancer ClarityDX Prostate® is 147% more specific than the PSA test for predicting clinically significant prostate cancer. Using ClarityDX Prostate® as a reflex test vs. PSA test alone could have resulted in 37% fewer unnecessary biopsies. The clinical study recruited men from two sites in Alberta, Canada, and one site ...
-
Nanostics Receives CE Mark for its ClarityDX Prostate Test to Detect Clinically Significant Prostate Cancer
Nanostics’ biomarker and machine learning-powered test, ClarityDX Prostate®, received a CE-IVD Mark. A CE-IVD Mark is required for all in vitro diagnostic (IVD) devices to be placed in the European Economic Area, Iceland, Norway, and Liechtenstein and allows Nanostics to market and sell ClarityDX Prostate® in these countries. The ClarityDX Prostate® test provides patients ...
-
Assessment of a urinary TRUS/biomarker-based risk score as inclusion criteria for multiparametric MRI to detect clinically significant prostate cancer
BACKGROUND Non-invasive techniques like urinary biomarkers and multiparametric Magnetic Resonance Imaging (mpMRI) show great promise for the detection of clinically significant prostate cancer (PCa), leading to a reduction of over-diagnosis and over-treatment. Apart from yet to be established diagnostic accuracy is the systematic use of mpMRI challenging due to the high cost of setting up, ...
By MDxHealth
-
Nanostics Announces the Launch of its Bladder Cancer Clinical Study Identifying Disease Predictors for Early Detection of Bladder Cancer
Clinical study launched in June 2022 with patient recruitment in Alberta with plans to expand to further sites across North America. The aim of the study is to validate a novel and minimally invasive liquid biopsy test for bladder cancer diagnosis using Nanostics’ ClarityDX® diagnostic platform. The study is supported in part by the Alberta Innovates AICE-Concepts Program with a ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you